The FDA has approved Datroway® (datopotamab deruxtecan-dlnk) for adult patients with unresectable or metastatic HR-positive, ...

Oncolytics Biotech received approval from Germany\u2019s Paul-Ehrlich-Institute to advance Cohort 5 of the GOBLET study, ...

Ariceum Therapeutics announced that the FDA has cleared its investigational new drug application to commence a Phase I/II ...

The Internet of Medical Things (IoMT) is set to radically change the quality of care and outcomes for millions of patients, while also increasing efficiency for clinicians and the organisations ...

The FDA has approved a novel combination therapy using Lumakras® (sotorasib) and Vectibix® (panitumumab) for adults with KRAS ...

Artificial Intelligence (AI) can play a crucial role in drug discovery, but the lack of sufficient data in this area remains a significant obstacle. Verseon’s newly developed AI technology, VersAI™, ...

Datopotamab deruxtecan (Dato-DXd) has been granted Priority Review from the US FDA for advanced EGFR-mutated non-small cell lung cancer (NSCLC) following prior therapies.